Cetera Advisor Networks’s Galectin Therapeutics GALT Stock Holding History

Cetera Advisor Networks’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-16,006	Closed	-$35K	–	1907
2021 Q1	$35K	Hold	16,006	–	–	﹤0.01%	1468
2020 Q4	$36K	Hold	16,006	–	–	﹤0.01%	1340
2020 Q3	$43K	Sell	16,006 -455	-3%	-$1.27K	﹤0.01%	1228
2020 Q2	$50K	Hold	16,461	–	–	﹤0.01%	1883
2020 Q1	$32K	Hold	16,461	–	–	﹤0.01%	1103
2019 Q4	$47K	Hold	16,461	–	–	﹤0.01%	1228
2019 Q3	$60K	Sell	16,461 -2,560	-13%	-$9.25K	﹤0.01%	1170
2019 Q2	$79K	Hold	19,021	–	–	﹤0.01%	1159
2019 Q1	$96K	Hold	19,021	–	–	﹤0.01%	1113
2018 Q4	$66K	Sell	19,021 -14,700	-44%	-$70.2K	﹤0.01%	1014
2018 Q3	$203K	Hold	33,721	–	–	0.01%	1045
2018 Q2	$215K	Buy	+33,721	New	+$164K	0.01%	752
2018 Q1	–	Sell	-15,721	Closed	-$53K	–	893
2017 Q4	$53K	Hold	15,721	–	–	﹤0.01%	975
2017 Q3	$34K	Hold	15,721	–	–	﹤0.01%	907
2017 Q2	$38K	Buy	+15,721	New	+$41.9K	﹤0.01%	910

Other funds holding GALT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

GWM

Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CCB

Cutter & Co Brokerage Ballwin, Missouri $423M AUM 15.02% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cetera Advisor Networks's GALT Position: Q2 2021 in Review

Cetera Advisor Networks sold out of Galectin Therapeutics (GALT) in Q2 2021, closing a stake of 16,006 shares — an estimated $35K sold.

Cetera Advisor Networks first reported a position in GALT in Q2 2017 and held it in 15 quarters. The position peaked at $215K in Q2 2018. 75 funds tracked by Wall St. Rank hold GALT as of Q2 2021.

Cetera Advisor Networks reported no remaining Galectin Therapeutics position as of Q2 2021 after selling out during the quarter.
Cetera Advisor Networks sold 16,006 Galectin Therapeutics shares in Q2 2021, an estimated $35K.
Cetera Advisor Networks first reported a position in Galectin Therapeutics in Q2 2017 and held it in 15 quarters.
Cetera Advisor Networks's Galectin Therapeutics position peaked at $215K in Q2 2018.
75 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2021.

Based on Cetera Advisor Networks's 13F filing for Q2 2021, filed 13 Aug 2021.